Published in Breast Cancer Res Treat on October 26, 2010
Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol (2012) 3.47
Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care (2012) 3.11
Understanding the benefit of metformin use in cancer treatment. BMC Med (2011) 2.28
Metformin: multi-faceted protection against cancer. Oncotarget (2011) 2.00
The role of obesity in cancer survival and recurrence. Cancer Epidemiol Biomarkers Prev (2012) 1.75
Future directions in cancer prevention. Nat Rev Cancer (2012) 1.62
Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol (2012) 1.45
Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer (2013) 1.39
Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis (2014) 1.35
Nutrient restriction and radiation therapy for cancer treatment: when less is more. Oncologist (2013) 1.20
Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat (2011) 1.15
Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care (2013) 1.15
Targeted therapy for breast cancer prevention. Front Oncol (2013) 1.12
New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells. Biomed Res Int (2014) 1.08
Metformin use and endometrial cancer survival. Gynecol Oncol (2013) 1.06
Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle (2012) 1.03
Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin. Oncotarget (2013) 1.01
Calorie restriction and cancer prevention: a mechanistic perspective. Cancer Metab (2013) 1.01
Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat (2011) 1.01
Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). BMC Cancer (2014) 1.00
Metformin as an energy restriction mimetic agent for breast cancer prevention. J Carcinog (2011) 1.00
The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer (2013) 0.96
Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol (2014) 0.93
Obesity and cancer pathogenesis. Ann N Y Acad Sci (2014) 0.93
Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning. Oncol Lett (2016) 0.89
Molecular Pathways: Is AMPK a Friend or a Foe in Cancer? Clin Cancer Res (2015) 0.87
Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res (2015) 0.86
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes. Breast Cancer Res (2015) 0.85
Long-term use of metformin and the molecular subtype in invasive breast carcinoma patients - a retrospective study of clinical and tumor characteristics. BMC Cancer (2014) 0.84
Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models. Cancer Prev Res (Phila) (2015) 0.84
Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer. Curr Breast Cancer Rep (2014) 0.83
Metformin inhibits growth of lung adenocarcinoma cells by inducing apoptosis via the mitochondria-mediated pathway. Oncol Lett (2015) 0.81
The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link. Front Endocrinol (Lausanne) (2015) 0.80
Evaluating the feasibility of performing window of opportunity trials in breast cancer. Int J Surg Oncol (2015) 0.80
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat (2012) 0.80
Obesity and cancer, a case for insulin signaling. Cell Death Dis (2015) 0.79
Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy. J Clin Oncol (2016) 0.79
Attenuating tumour angiogenesis: a preventive role of metformin against breast cancer. Biomed Res Int (2015) 0.78
Synergistic cell death in FLT3-ITD positive acute myeloid leukemia by combined treatment with metformin and 6-benzylthioinosine. Leuk Res (2016) 0.77
Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors. Contemp Clin Trials (2015) 0.77
Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. Trials (2013) 0.76
Carcinogenic effects of oil dispersants: A KEGG pathway-based RNA-seq study of human airway epithelial cells. Gene (2016) 0.75
AMP-activated protein kinase and energy balance in breast cancer. Am J Transl Res (2017) 0.75
Metformin: are potential benefits on cancer risk extended to cancer survival? Oncologist (2013) 0.75
Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study. Cancer Causes Control (2016) 0.75
Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator. Oncoimmunology (2016) 0.75
Biomarkers of cancer angioprevention for clinical studies. Ecancermedicalscience (2015) 0.75
High prevalence of diabetes mellitus and impaired glucose tolerance in liver cancer patients: A hospital based study of 4610 patients with benign tumors or specific cancers. F1000Res (2016) 0.75
Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group Perspective. Can Urol Assoc J (2011) 0.75
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. J Clin Oncol (2017) 0.75
Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 16.79
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.55
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (2013) 9.01
SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med (2013) 8.21
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol (2004) 7.36
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol (2006) 6.24
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol (2007) 6.11
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol (2011) 5.67
Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst (2009) 5.62
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol (2010) 5.25
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med (2010) 5.17
HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med (2006) 5.10
Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med (2015) 4.94
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ (2010) 4.73
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol (2011) 4.67
Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease. JAMA (2013) 4.67
Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol (2002) 4.55
Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol (2005) 4.31
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med (2012) 4.10
Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol (2007) 3.92
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys (2009) 3.91
Metformin in breast cancer: time for action. J Clin Oncol (2009) 3.81
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol (2006) 3.42
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol (2008) 3.40
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol (2010) 3.32
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol (2013) 3.24
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol (2009) 3.18
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol (2007) 3.12
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol (2009) 2.97
Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med (2005) 2.86
The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer (2007) 2.84
Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol (2002) 2.75
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol (2006) 2.74
PGA: power calculator for case-control genetic association analyses. BMC Genet (2008) 2.71
Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst (2007) 2.70
Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging (2006) 2.69
Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol (2007) 2.69
Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer. J Clin Oncol (2012) 2.59
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol (2013) 2.59
Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol (2011) 2.58
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol (2011) 2.57
Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer (2008) 2.53
Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol (2009) 2.49
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
Epidemiology of inflammatory breast cancer (IBC). Breast Dis (2006) 2.46
Localization of Rheb to the endomembrane is critical for its signaling function. Biochem Biophys Res Commun (2006) 2.45
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med (2011) 2.32
Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst (2014) 2.30
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst (2013) 2.28
Understanding the benefit of metformin use in cancer treatment. BMC Med (2011) 2.28
Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol (2006) 2.26
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol (2014) 2.25
Are cancer-related decision aids effective? A systematic review and meta-analysis. J Clin Oncol (2009) 2.24
Trends in relative survival for ovarian cancer from 1975 to 2011. Obstet Gynecol (2015) 2.22
Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol (2005) 2.20
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol (2007) 2.15
Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol (2011) 2.15
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol (2013) 2.12
Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol (2005) 2.11
Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol (2005) 2.11
Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol (2008) 2.10
Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol (2013) 2.05
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol (2009) 2.04
Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause (2007) 2.04
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol (2011) 2.01
Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol (2011) 2.00
Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol (2013) 1.99